Oregon Health & Science University
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oregon Health & Science University
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
In Vivo's editors pick October's most significant deals, including bold moves from Vir Biotechnology and the birth of a major generics player. (Free article.)
Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised more than $500m and signed multiple collaboration agreements, including deals with Alnylam and Visterra worth as much as $1bn each.
- Academic and Research Institutions
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.